The Existing Challenge

Drug-resistance is the major hurdle facing oncology
Cancers such as pancreatic cancer are inherently poorly sensitive
Almost all other cancers develop resistance over time
In spite of considerable effort, no drug has come to market that performs this task
Overcoming resistance to common chemotherapies would revolutionise cancer medicine

A New Approach

Idronoxil is a potent sensitiser of standard chemotherapies in-vivo
This effect however failed in late-stage human trials
We believe we have uncovered the reason for this failure
NOX-66 is a completely new dosage formulation of idronoxil designed to overcome this failure

To improve the performance of most commonly-used chemotherapy drugs
To enable such drugs to be used at lower and safer dosages
To see NOX-66 become standard therapy in conjunction with all forms of cytotoxic chemotherapy in both early and late-stage cancers
To develop the next generation of resistance-removal drugs and their delivery